Comparing radical radiotherapy and surgery for renal pelvis cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to recruit 30 patients with renal pelvis cancer to compare the effectiveness of radical radiotherapy versus radical surgery. Patients will be divided into two groups based on their treatment choice: one receiving standard nephroureterectomy and the other receiving stereotactic body radiation therapy (SBRT) or moderately segmented radical radiotherapy. The study will assess short-term efficacy using imaging and RECIST criteria one month after treatment, focusing on disease-free survival and potential remission rates. The study will also consider patient factors such as age and overall health in determining eligibility for surgery or radiotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Uroepithelial carcinoma of the renal pelvis or ureter supported by clinical symptoms, imaging, histopathology, urocytology, or fluorescence in situ hybridisation (FISH), or those who satisfy FISH positivity despite the absence of pathology or the patient's refusal to be punctured and who are judged to have a renal pelvic or ureteral carcinoma by an imaging physician and a urologist on the basis of CTU or MRU or PETCT; No distant metastases were detected on full screening; Patients who are unable to undergo surgical treatment due to poor general condition, inability to be anaesthetised or to tolerate surgery, or refusal to undergo surgery; patients who are over 70 years old; or patients who are less than 70 years old combined with underlying diseases or the presence of regional lymph node metastasis, etc. who are otherwise unable to undergo radical surgery; Expected survival ≥ 6 months; Willingness and ability to comply with trial and follow-up procedural arrangements; voluntarily agree to participate in the study and sign an informed consent form.

Exclusion Criteria:

* Previous abdominopelvic radiotherapy; Other serious, uncontrolled concomitant disease that may affect adherence to the protocol or interfere with interpretation of results; Other malignancies within 5 years prior to the start of study dosing, with the exception of malignancies that can be expected to resolve with treatment (including, but not limited to, adequately treated thyroid cancer, cervical cancer in situ, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated by radical surgery); estimated that patients' adherence to participation in this clinical study was insufficient.

Where it's running

• Departmeng of Urology, Peking University First Hospital
  Beijing, China Recruiting
• Department of Radiotherapy Oncology, Peking University First Hospital
  Beijing, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LY4052031 for advanced or metastatic urothelial and other nectin‑4–expressing solid tumors

  This trial will test whether LY4052031 is safe and can help people with advanced or metastatic urothelial cancer or other solid tumors that express nectin‑4.

  Recruiting at 36 sites Phase 1 Eli Lilly and Company · Duarte, California and 39 other locations · NCT06465069

• Registry of patients with upper tract urothelial cancer treated with Jelmyto

  This study is looking at how well Jelmyto works for people with upper tract urothelial cancer by tracking their experiences and outcomes over time.

  Recruiting at 22 sites UroGen Pharma Ltd. · Santa Monica, California and 21 other locations · NCT05874921

• Comparing gemcitabine and water irrigation for bladder cancer recurrence prevention

  This study is testing whether using gemcitabine or sterile water after surgery can help prevent bladder cancer from coming back in patients who had their kidney and ureter removed.

  Recruiting Phase 3 University of Texas Southwestern Medical Center · Dallas, Texas · NCT04865939

• Using ST-02 to treat low-grade upper tract urothelial carcinoma

  This study is testing a new treatment called ST-02 to see if it can safely help people with low-grade upper tract urothelial carcinoma feel better after receiving weekly treatments for six weeks.

  Recruiting at 6 sites Phase 2/3 University of British Columbia · Vancouver, British Columbia and 7 other locations · NCT06124976

• Combination of Enfortumab Vedotin and Pembrolizumab with Surgery for Advanced Bladder Cancer

  This study is testing if a combination of two medications, enfortumab vedotin and pembrolizumab, can help people with advanced bladder cancer before they have surgery.

  Recruiting Phase 4 Mayo Clinic · Rochester, Minnesota · NCT06764095

• Therapeutic plasma exchange plus enfortumab vedotin and pembrolizumab for bladder and upper urinary tract urothelial cancer

  This trial will test whether doing a therapeutic plasma exchange before giving enfortumab vedotin (an antibody‑drug conjugate) and pembrolizumab (an immune checkpoint inhibitor) helps people with metastatic or refractory urothelial (bladder or upper tract) cancer who have progressed on prior therapies.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07087860

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.